Pneumonias in immunocompromised patients: improvement of treatment using the immunomodulator

Authors

  • Inna Borisova SE «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine» Volodymyra Vernadskogo str., 9, Dnepr, Ukraine, 49044, Ukraine https://orcid.org/0000-0001-5117-6012
  • Tetyana Pertseva SE «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine» Volodymyra Vernadskogo str., 9, Dnepr, Ukraine, 49044, Ukraine

DOI:

https://doi.org/10.15587/2519-4798.2017.111188

Keywords:

pneumonia, immunity disorders, glutamyl-cysteinile-glycine disodium, cellular and humoral immunity indices

Abstract

Aim of research: to optimize the approach to the treatment of pneumonias in patients on the background of acute leucosis from positions of immunoresistance based on using disodium glutamyl-cysteinile-glycine by the method of extracorporal pharmacotherapy.

Materials and methods. Research group – 39 patients with pneumonia on the background of acute leucosis, who underwent the treatment according to the form and stage of the disease on the base of the hematological center “MI city multi-profile clinical hospital No. 4» Dnipro city, 2015–2016. Mean age of patients 31,5±6,5 years, 11 women and 38 men. Patients of the main group were additionally administered with disodium glutamyl-cysteinile-glycine in 2 ml of 3 % solution (60 mg) i/v No. 5 each second day. The parameters of the immune response were studied: Т and В-lymphocytes and their subpopulational composition (CD3+, CD4+, CD8+, CD19+, CD16+, CD56+) by the method of flow laser cytoflourometry (BeckmanCoulter–USA). There were additionally determined; immunoregulatory index, leuco T-cellular index, leuco B-cellular index and index of leucocytes activation; phagocytosis state was assessed by the parameters: phagocytic number, phagocytic indicator, NBT-tests. The state of humoral immunity was assessed by levels of immunoglobulins of classes A, M and G by the method of immunoturbidimetry (BeckmanCoulter–USA).

Results. The analysis of parameters of cellular and humoral immunity of patients with pneumonias on the background of AL by the improved method of treatment of pneumonia using the immunomodeling preparation disodium glutamyl-cysteinile-glycine proved the positive influence on the immune reactivity of patients’ organism, manifested by the reliable increase of the relative quantity of the pool of T-helpers (CD4+), NК-cells, increase of immunoregulatory index, PI, PN and increase of humoral immunity indices.

Conclusions. The improved method of pneumonia treatment on the background of AL using the immunomodeling preparation disodium glutamyl-cysteinile-glycine by ECPT method proved the positive influence of the immune reactivity of patients’ organism, manifested by the reliable activation of phagocytosis and anti-infectious protection, manifested by the more expressed effect of pneumonia treatment: improvement of the clinical course of disease; decrease of the prognosticated number of ABT days and earlier return to the program treatment of AL. The obtained effects of the improved method of pneumonia treatment in patients with acute leucosis at using the immunomodeling preparation disodium glutamyl-cysteinile-glycine by ECPT method proves the pathogenetic validity of the possibility of optimization of pneumonia treatment from positions of immunoresistance

Author Biographies

Inna Borisova, SE «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine» Volodymyra Vernadskogo str., 9, Dnepr, Ukraine, 49044

PhD, Postgraduate student

Department of Medical and Social Expertise and Rehabilitation

Tetyana Pertseva, SE «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine» Volodymyra Vernadskogo str., 9, Dnepr, Ukraine, 49044

MD, Professor, corresponding member of NAMS

Department of Internal Medicine No. 1

References

  1. Galstyan, G. M., Klyasova, G. A., Katrysh, S. A., Zolotovskaya, I. K., Galstyan, A. G., Gorodetskiy, V. M. (2011). Etiologiya nozokomial'nyh pnevmoniy u onkogematologicheskih bol'nyh v otdelenii reanimatsii i intensivnoy terapii. Klinicheskaya mikrobiologiya i antimikrobnaya himioterapiya, 3, 231–240.
  2. Rukavitsyn, O. A. (Ed.) (2015). Gematologiya. Moscow: GEOTAR-Media, 776.
  3. Rumyantsev, A. G., Maschan, A. A., Samochatova, E. V. (2009). Soprovoditel'naya terapiya i kontrol' infektsiy pri gematologicheskih i onkologicheskih zabolevaniyah. Moscow: Medpraktika-M, 448.
  4. Feshchenko, Yu. I., Holubovska, O. A., Honcharov, K. A. (2012). Nehospitalna pnevmoniya u doroslykh osib: etiolohiya, patohenez, klasyfikatsiya, diahnostyka, antybiotybakterialna terapiya (Proekt klinichnykh nastanov). Ukr. pulmonol. Zhurnal, 4, 5–17.
  5. Feshchenko, Yu. I., Rekalova, E. M. (2013). Terapevticheskie vozmozhnosti innovatsionnogo imunomodulyatora v pul'monologii i ftiziatrii. Astma ta alerhiya, 1, 6–12.
  6. Parahonskiy, A. P. (2017). Narusheniya immunnoy sistemy u bol'nyh pnevmoniey i metody ih korrektsii. Sovremennye problemy allergologii i immunologii. Available at: http://econf.rae.ru/pdf/2004/07/Parahonskii_2.pdf
  7. Kozhemyakin, L. A. (2002). Mekhanizmy deystviya preparata Glutoksim. Opportunisticheskie infektsii: problemy i perspektivy. Omsk: Omskaya meditsinskaya akademiya, 50–53.
  8. Shvetsov, D. A. (1996). Napravlenyy transport antibiotikov v lechenii ostryh nespetsificheskih vospalitel'nyh zabolevaniy lyogkih i plevry. Karaganda, 22.
  9. Standarty diahnostyky ta likuvannia onkolohichnykh khvorykh (2007). Nakaz MOZ Ukrainy «Pro zatverdzhennia protokoliv nadannia medychnoi dopomohy za spetsialnistiu «Onkolohiia» vid 17.09.2007 r. No. 554 iz dopovnenniamy zghidno Nakazu MOZ Ukrainy No. 645 vid 30.07.2010 r.
  10. Nehospitalna ta nozokomialna (hospitalna) pnevmoniya u doroslykh osib: etiolohiya, patohenez, klasyfikatsiya, diahnostyka, antybakterialna terapiya (metodychni rekomendatsyi) (2007). Nakaz MOZ Ukrainy «Pro zatverdzhennia klinichnykh protokoliv nadannia medychnoi dopomohy za spetsialnistiu «Pulmonolohiya» vid 19.03.2007 r. No. 128. Kyiv: Veles, 105–146.
  11. Borysova, I., Pertseva, T., Kaplan, P. (2016). Pat. No. 1007559U UA. Sposib likuvannia pnevmonyi na tli hostrykh leikoziv hlutoksymom. MPK A61K 31/451 (2006.01), A 61R 31/00, A61R37/00. No.113883; declareted: 19.04.2016; published: 27.02.2017, Bul. No. 4, 8.
  12. Glants, S. (1998). Mediko-biologicheskaya statistika. Moscow: Praktika, 459.
  13. Serediuk, N. M., Bardiak, Ye. M. (2012). Doslidzhennia imunnykh porushen u khvorykh iz riznymy formamy hemoblastoziv ta suputnim zahostrenniam khronichnoho piielonefrytu. Ukr. zhurn. klinichn. ta laborator. Medytsyny, 7 (4), 56–59.
  14. Pardoll, D. M., Topalian, S. L. (1998). The role of CD4+ T cell responses in antitumor immunity. Current Opinion in Immunology, 10 (5), 588–594. doi: 10.1016/s0952-7915(98)80228-8
  15. Feshchenko, Yu. I., Ishchuk, S. G., Matvienko, Yu. A. (2012). Osobennosti sovremennoy immunomoduliruyushchey terapii. Ukr. pul'monol. zhurnal, 3, 50–53.
  16. Easton, D. M., Nijnik, A., Mayer, M. L., Hancock, R. E. W. (2009). Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends in Biotechnology, 27 (10), 582–590. doi: 10.1016/j.tibtech.2009.07.004
  17. Mostovoi, Yu. M. (2013). Dosvid zastosuvannia imunomodeliuiuchoi terapyi Hlutoksymom u khvorykh iz tiazhkym perebihom ne hospitalnoi pnevmonyi. Pulmonolohiya, 12, 52–53.
  18. Shvetsov, D. A. (1996). Napravlennyy transport antibiotikov v lechenii ostryh nespetsificheskih vospalitel'nyh zabolevaniy legkih i plevry. Karaganda, 22.
  19. Protopopova, G. M., Vlasov, S. V., Kreynes, V. M. (1998). Reinfuziya kletochnoy massy krovi posle ee inkubatsii s antibiotikom v lechenii neoslozhnennoy pnevmonii u detey. Efferentnaya terapiya, 4 (4), 47–50.

Downloads

Published

2017-09-30

How to Cite

Borisova, I., & Pertseva, T. (2017). Pneumonias in immunocompromised patients: improvement of treatment using the immunomodulator. ScienceRise: Medical Science, (9 (17), 21–27. https://doi.org/10.15587/2519-4798.2017.111188

Issue

No. 9 (17) (2017)

Section

Medical Science

License

Copyright (c) 2017 Inna Borisova, Tetyana Pertseva

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.